ethylene glycol monoethyl ether acetate profile

Ethylene glycol monoethyl ether acetate (EGMEA), also known as 2-ethoxyethyl acetate, is a colorless liquid with a mild, sweet odor. It is a solvent commonly used in coatings, inks, and adhesives. EGMEA is synthesized by the esterification of ethylene glycol monoethyl ether with acetic acid. It is known to be a good solvent for a wide range of organic compounds and has relatively low toxicity. EGMEA's low volatility and good solvency make it a desirable solvent for many applications. Researchers study EGMEA due to its potential applications in various industries and to ensure its safe handling and environmental impact are understood.'

Cross-References

ID Source	ID
PubMed CID	8095
CHEMBL ID	1427293
SCHEMBL ID	24056
MeSH ID	M0078068

Synonyms (104)

Synonym
oxytol acetate
nsc-8658
acetate de l'ether monoethylique de l'ethylene-glycol
2-ethoxyethanol acetate
2-ethoxyethyl acetate
glycol monoethyl ether acetate
oxitol acetate
ethoxyethyl acetate
cellosolve acetate
acetato di cellosolve
csac
wln: 2o2ov1
2-ethoxyethanol, ester with acetic acid
ethyl glycol acetate
.beta.-ethoxyethyl acetate
2-etossietil-acetato
ethyl cellosolve acetaat
111-15-9
''cellosolve'' acetate
aethylenglykolaetheracetat
2-ethoxyethyle, acetate de
acetate de cellosolve
acetate d'ethylglycol
octan etoksyetylu
ethylglykolacetat
nsc8658
acetic acid, 2-ethoxyethyl ester
1-acetoxy-2-ethoxyethane
2-aethoxy-aethylacetat
ethyl cellosolve acetate
ethylene glycol ethyl ether acetate
ethylene glycol monoethyl ether acetate
2-ethoxy-ethylacetaat
ethanol, 2-ethoxy-, acetate
NCGC00091657-01
egeea
ethyleneglycol monoethyl ether acetate
2-ethoxyethyle, acetate de [french]
nsc 8658
2-ethoxyethylacetate
glycol ether ee acetate
ethyl cellosolve acetaat [dutch]
ccris 3286
acetate de l'ether monoethylique de l'ethylene-glycol [french]
2-etossietil-acetato [italian]
acetate de cellosolve [french]
ektasolve ee acetate solvent
aethylenglykolaetheracetat [german]
ai3-01955 (usda)
einecs 203-839-2
acetate d'ethylglycol [french]
un1172
ethoxyethanol, 2-, acetate
acetato di cellosolve [italian]
ethylglycol acetate
2-ethoxy-ethylacetaat [dutch]
ethylene glycol monoethyl ether monoacetate
2-aethoxy-aethylacetat [german]
ethoxyethanol acetate
2-ethoxyethylester kyseliny octove [czech]
celosolvacetat [czech]
octan etoksyetylu [polish]
ethylglykolacetat [german]
hsdb 539
brn 1748677
2-ethoxyethyl acetate, 98%
MLS002454405
smr001253877
E0049
acetic acid 2-ethoxyethyl ester
NCGC00091657-03
NCGC00091657-02
tox21_400028
dtxsid9021928 ,
dtxcid701928
cas-111-15-9
celosolvacetat
ethylene glycol monoethyl ether acetate [un1172] [flammable liquid]
dg1o0z7390 ,
unii-dg1o0z7390
ethanol, 2-ethoxy-, 1-acetate
2-ethoxyethylester kyseliny octove
FT-0626331
AKOS015901418
SCHEMBL24056
2-ethoxyethanol 1-acetate
ethoxyethanol acetate [inci]
2-ethoxyethyl acetate [mi]
ethylene glycol monoethyl ether acetate [hsdb]
beta-ethoxyethyl acetate
CHEMBL1427293
2-ethoxyethyl ester of acetic acid
un 1172
J-521344
J-002533
mfcd00009251
2-ethoxyethyl acetate, saj first grade, >=98.0%
2-ethoxyethyl acetate, certified reference material, tracecert(r)
acetic acid-2-ethoxyethyl ester
2-ethoxyethyl acetae
Q209376
acetic acid-2-ethoxyethyl ester 1000 microg/ml in acetonitrile
acetic acid 2-ethoxy-ethyl ester
ethylene glycol monobuty ether aceate

Excerpt	Reference	Relevance
" The goals of the work reported here were to develop physiologically based pharmacokinetic (PBPK) models of EGEEA and EGEE for pregnant rats and humans."	( A toxicokinetic study of inhaled ethylene glycol ethyl ether acetate and validation of a physiologically based pharmacokinetic model for rat and human. Corley, RA; Gargas, ML; Hays, SM; Mast, TJ; Paustenbach, DJ; Sweeney, LM; Tyler, TR; Weitz, KK, 2000)	0.31

Excerpt	Reference	Relevance
" The results show that glycol ethers are very well absorbed through the skin."	( Occupational chronic exposure to organic solvents. XIV. Examinations concerning the evaluation of a limit value for 2-ethoxyethanol and 2-ethoxyethyl acetate and the genotoxic effects of these glycol ethers. Angerer, J; Letzel, S; Rüdiger, HW; Söhnlein, B; Weltle, D, 1993)	0.29
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" After IV dosing with 1 mg/kg [ethyl-1,2-14C]PEA, the urine contained 61% and 88% of the dose in 4 and 24 hr, respectively."	( Pulmonary and percutaneous absorption of 2-propoxyethyl acetate and 2-ethoxyethyl acetate in beagle dogs. Deisinger, PJ; DiVincenzo, GD; Guest, D; Hamilton, ML, 1984)	0.27
" Minor liver and kidney damage was also seen in short-term studies of rats injected subcutaneously with Ethoxyethanol, but was absent in dogs dosed intravenously."	( Final report on the safety assessment of ethoxyethanol and ethoxyethanol acetate. Johnson, W, 2002)	0.31

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	39.9149	0.0025	41.7960	15,848.9004	AID1347398
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	27.3060	0.0060	38.0041	19,952.5996	AID1159521
GLI family zinc finger 3	Homo sapiens (human)	Potency	1.2197	0.0007	14.5928	83.7951	AID1259369
AR protein	Homo sapiens (human)	Potency	35.4813	0.0002	21.2231	8,912.5098	AID588515
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	25.1189	0.0112	12.4002	100.0000	AID1030
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	10.0000	0.0013	18.0743	39.8107	AID926; AID938
progesterone receptor	Homo sapiens (human)	Potency	27.3060	0.0004	17.9460	75.1148	AID1346784
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	47.9478	0.0030	41.6115	22,387.1992	AID1159552; AID1159553
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	17.3739	0.0008	17.5051	59.3239	AID1159527
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	43.2410	0.0015	30.6073	15,848.9004	AID1224841; AID1224848; AID1224849
pregnane X nuclear receptor	Homo sapiens (human)	Potency	43.2771	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	19.4938	0.0002	29.3054	16,493.5996	AID743069
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	3.1623	0.0010	24.5048	61.6448	AID588535
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	48.9662	0.0237	23.2282	63.5986	AID743223
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	61.1306	0.0007	23.0674	1,258.9301	AID743085
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	43.2771	0.0003	23.4451	159.6830	AID743066
Nuclear receptor ROR-gamma	Homo sapiens (human)	Potency	0.9439	0.0266	22.4482	66.8242	AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
xenobiotic metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of glucose metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of steroid metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor ROR-gamma	Homo sapiens (human)
circadian regulation of gene expression	Nuclear receptor ROR-gamma	Homo sapiens (human)
cellular response to sterol	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of circadian rhythm	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of fat cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear receptor ROR-gamma	Homo sapiens (human)
adipose tissue development	Nuclear receptor ROR-gamma	Homo sapiens (human)
T-helper 17 cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear body	Nuclear receptor ROR-gamma	Homo sapiens (human)
chromatin	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay ID	Title	Year	Journal	Article
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	9 (26.47)	18.7374
1990's	9 (26.47)	18.2507
2000's	7 (20.59)	29.6817
2010's	3 (8.82)	24.3611
2020's	6 (17.65)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (5.88%)	6.00%
Case Studies	1 (2.94%)	4.05%
Observational	0 (0.00%)	0.25%
Other	31 (91.18%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ethylene glycol Ethylene Glycol: A colorless, odorless, viscous dihydroxy alcohol. It has a sweet taste, but is poisonous if ingested. Ethylene glycol is the most important glycol commercially available and is manufactured on a large scale in the United States. It is used as an antifreeze and coolant, in hydraulic fluids, and in the manufacture of low-freezing dynamites and resins.. ethanediol : Any diol that is ethane or substituted ethane carrying two hydroxy groups.. ethylene glycol : A 1,2-glycol compound produced via reaction of ethylene oxide with water.	2.02	1	ethanediol; glycol	metabolite; mouse metabolite; solvent; toxin
phenol [no description available]	1.98	1	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
methylene chloride Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology.. dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea.	1.98	1	chloromethanes; volatile organic compound	carcinogenic agent; polar aprotic solvent; refrigerant
n-methylaminoethanol N-methylaminoethanol: structure. N-methylethanolamine : An ethanolamine compound having an N-methyl substituent.	1.96	1	ethanolamines
methyl cellosolve methyl cellosolve: widely used industrial solvent for resins, lacquers, dyes & inks; may cause anemia macrocytosis, appearance of young granulocytes in blood; RN given refers to parent cpd	2.67	3	glycol ether	protic solvent; solvent
2-methoxyethanol acetate [no description available]	2.66	3
2-ethoxyethanol 2-ethoxyethanol : A hydroxyether that is the ethyl ether derivative of ethylene glycol.	5.09	8	glycol ether; primary alcohol	protic solvent; teratogenic agent
n-butoxyethanol n-butoxyethanol: RN given refers to parent cpd; structure. 2-butoxyethanol : A primary alcohol that is ethanol in which one of the methyl hydrogens is replaced by a butoxy group. A high-boiling (171degreeC) colourless liquid, it is used as a solvent for paints and inks, as well as in some dry cleaning solutions.	2.66	3	glycol ether; primary alcohol	protic solvent
carbitol carbitol: used as lubricating oil & in braking fluid, structure. diethylene glycol monoethyl ether : A primary alcohol that is ethanol substituted by a 2-ethoxyethoxy group at position 2.	1.96	1	diether; glycol ether; hydroxypolyether; primary alcohol	protic solvent
diglyme diglyme : A polyether that is the dimethyl ether derivative of diethylene glycol.	1.98	1	polyether	environmental contaminant; solvent; xenobiotic
ethoxyacetic acid [no description available]	7.89	4	carboxylic acid
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	2.89	4	benzenes; phenyl acetates

Condition	Relationship Strength	Studies
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Acute Liver Injury, Drug-Induced [description not available]	2.04	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.04	1
Diseases, Occupational [description not available]	2.7	3
Dermatoses [description not available]	2.05	1
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	2.05	1
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	4.46	5
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	3.22	6
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.66	3
Fetal Death Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.	1.96	1
Birth Weight The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.	1.99	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.98	1
Blood Diseases [description not available]	2	1
Hematologic Diseases Disorders of the blood and blood forming tissues.	2	1
Reproductive Sterility [description not available]	2.89	1
Infertility A reduced or absent capacity to reproduce.	2.89	1
Embryopathies [description not available]	1.97	1
Hypospadias A birth defect due to malformation of the URETHRA in which the urethral opening is below its normal location. In the male, the malformed urethra generally opens on the ventral surface of the PENIS or on the PERINEUM. In the female, the malformed urethral opening is in the VAGINA.	1.97	1

ethylene glycol monoethyl ether acetate

Cross-References

Synonyms (104)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (17)

Potency Measurements

Biological Processes (13)

Molecular Functions (10)

Ceullar Components (4)

Bioassays (33)

Research

Studies (34)

Market Indicators

Research Demand Index: 40.02

Study Types

ethylene glycol monoethyl ether acetate

Cross-References

Synonyms (104)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (17)

Potency Measurements

Biological Processes (13)

Molecular Functions (10)

Ceullar Components (4)

Bioassays (33)

Research

Studies (34)

Market Indicators

Research Demand Index: 40.02

Study Types

Related Drugs (12)

Related Conditions (20)